| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017640666 |
| P356 | DOI | 10.1038/AJG.2012.201 |
| P8608 | Fatcat ID | release_x2bawur3p5hqhicpd6nvl66z6a |
| P698 | PubMed publication ID | 22777337 |
| P50 | author | Jason A. Dominitz | Q37834477 |
| P2093 | author name string | Steven M Asch | |
| Fasiha Kanwal | |||
| Hashem El-Serag | |||
| Jennifer Kramer | |||
| Tuyen Hoang | |||
| Timothy Chrusciel | |||
| P2860 | cites work | Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. | Q45425549 |
| What do patients consider when making decisions about treatment for hepatitis C? | Q47604926 | ||
| Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. | Q50584684 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Patients' preferences for treatment of hepatitis C | Q33615461 | ||
| Clinical Case Registries: simultaneous local and national disease registries for population quality management | Q34407096 | ||
| Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors | Q34719654 | ||
| Computing inter-rater reliability and its variance in the presence of high agreement | Q34778830 | ||
| Exceptions to outpatient quality measures for coronary artery disease in electronic health records | Q37841981 | ||
| Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival | Q42990049 | ||
| Quality of care in patients with chronic hepatitis C virus infection: a cohort study | Q42999268 | ||
| Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study | Q43001380 | ||
| Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection | Q43571174 | ||
| Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre | Q43591832 | ||
| Gaps in the achievement of effectiveness of HCV treatment in national VA practice | Q43879719 | ||
| Predictors of response of US veterans to treatment for the hepatitis C virus | Q45332298 | ||
| Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection | Q45333052 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1512-1521 | |
| P577 | publication date | 2012-07-10 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | The performance of process measures in hepatitis C. | |
| P478 | volume | 107 |
| Q42251563 | Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection |
| Q41930106 | Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. |
| Q34577157 | Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients |
| Q38947375 | Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. |
| Q88917708 | Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C |
| Q41065322 | High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers |
| Q37678082 | Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities |
| Q37184472 | Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States |
| Q37721906 | Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit |
| Q47330339 | Process of care for hepatitis C infection is linked to treatment outcome and virologic response |
| Q40706124 | Quality of Care Provided by Hepatologists to Patients with Cirrhosis at Three Parallel Health Systems |
| Q93141224 | Quality of care assessment in chronic liver disease |
| Q40774593 | Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. |
| Q34808945 | Racial, social, and clinical determinants of hepatocellular carcinoma surveillance |
Search more.